317 related articles for article (PubMed ID: 28094431)
1. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
2. Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.
Jambhekar NA; Rekhi B; Thorat K; Dikshit R; Agrawal M; Puri A
Arch Pathol Lab Med; 2010 Aug; 134(8):1181-7. PubMed ID: 20670140
[TBL] [Abstract][Full Text] [Related]
3. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features of four rare types of chordomas, confirmed by brachyury immunostaining.
Rekhi B; Banerjee D; Ramadwar M; Bajpai J; Jambhekar NA
Indian J Pathol Microbiol; 2017; 60(3):350-354. PubMed ID: 28937370
[TBL] [Abstract][Full Text] [Related]
5. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis.
Oakley GJ; Fuhrer K; Seethala RR
Mod Pathol; 2008 Dec; 21(12):1461-9. PubMed ID: 18820665
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.
Sangoi AR; Dulai MS; Beck AH; Brat DJ; Vogel H
Am J Surg Pathol; 2009 May; 33(5):669-81. PubMed ID: 19194275
[TBL] [Abstract][Full Text] [Related]
7. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue.
Tirabosco R; Mangham DC; Rosenberg AE; Vujovic S; Bousdras K; Pizzolitto S; De Maglio G; den Bakker MA; Di Francesco L; Kalil RK; Athanasou NA; O'Donnell P; McCarthy EF; Flanagan AM
Am J Surg Pathol; 2008 Apr; 32(4):572-80. PubMed ID: 18301055
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
9. Brachyury expression in intracranial SMARCB1-deficient tumors: important points for distinguishing poorly differentiated chordoma from atypical teratoid/rhabdoid tumor.
Kohashi K; Yamamoto H; Yamada Y; Kinoshita I; Oda Y
Hum Pathol; 2021 Jun; 112():1-8. PubMed ID: 33741347
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.
Miettinen M; Wang Z; Lasota J; Heery C; Schlom J; Palena C
Am J Surg Pathol; 2015 Oct; 39(10):1305-12. PubMed ID: 26099010
[TBL] [Abstract][Full Text] [Related]
11. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.
Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P
Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396
[TBL] [Abstract][Full Text] [Related]
13. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
14. Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.
Zhang L; Guo S; Schwab JH; Nielsen GP; Choy E; Ye S; Zhang Z; Mankin H; Hornicek FJ; Duan Z
PLoS One; 2013; 8(9):e75851. PubMed ID: 24086644
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
16. Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury.
Clayton EF; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Apr; 17(2):192-7. PubMed ID: 23218904
[TBL] [Abstract][Full Text] [Related]
17. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
18. Patterns of brachyury expression in chordomas.
Dridi M; Boutonnat J; Dumollard JM; Peoc'h M; Karpathiou G
Ann Diagn Pathol; 2021 Aug; 53():151760. PubMed ID: 33989961
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
[TBL] [Abstract][Full Text] [Related]
20. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
